SI3472165T1 - N-(substituirani fenil)-sulfonamidni derivati kot inhibitorji kinaz - Google Patents
N-(substituirani fenil)-sulfonamidni derivati kot inhibitorji kinazInfo
- Publication number
- SI3472165T1 SI3472165T1 SI201731456T SI201731456T SI3472165T1 SI 3472165 T1 SI3472165 T1 SI 3472165T1 SI 201731456 T SI201731456 T SI 201731456T SI 201731456 T SI201731456 T SI 201731456T SI 3472165 T1 SI3472165 T1 SI 3472165T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phenyl
- substituted
- kinase inhibitors
- sulfonamide derivatives
- sulfonamide
- Prior art date
Links
- -1 N-(substituted-phenyl)-sulfonamide Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16175386 | 2016-06-21 | ||
| PCT/EP2017/064904 WO2017220477A1 (en) | 2016-06-21 | 2017-06-19 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
| EP17732075.1A EP3472165B1 (en) | 2016-06-21 | 2017-06-19 | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3472165T1 true SI3472165T1 (sl) | 2024-02-29 |
Family
ID=56148248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201731456T SI3472165T1 (sl) | 2016-06-21 | 2017-06-19 | N-(substituirani fenil)-sulfonamidni derivati kot inhibitorji kinaz |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10561660B2 (sl) |
| EP (1) | EP3472165B1 (sl) |
| JP (1) | JP6867417B2 (sl) |
| KR (1) | KR102500416B1 (sl) |
| CN (1) | CN109311894B (sl) |
| AU (1) | AU2017279878B9 (sl) |
| CA (1) | CA3029097A1 (sl) |
| DK (1) | DK3472165T3 (sl) |
| ES (1) | ES2964781T3 (sl) |
| FI (1) | FI3472165T3 (sl) |
| HU (1) | HUE064919T2 (sl) |
| IL (1) | IL263739B (sl) |
| MX (1) | MX2018016419A (sl) |
| PT (1) | PT3472165T (sl) |
| RU (1) | RU2753520C2 (sl) |
| SI (1) | SI3472165T1 (sl) |
| WO (1) | WO2017220477A1 (sl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102500416B1 (ko) * | 2016-06-21 | 2023-02-17 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체 |
| WO2021030238A2 (en) * | 2019-08-09 | 2021-02-18 | Ohm Oncology | Method of synthesis of compound for dual inhibition of jak2 and bet |
| KR20210056827A (ko) * | 2019-11-11 | 2021-05-20 | 일동제약(주) | 신규한 벤젠설폰아미드 유도체 및 그의 용도 |
| EP4107146A1 (en) * | 2020-02-17 | 2022-12-28 | Alesta Therapeutics BV | Gcn2 modulator compounds |
| MX2022013984A (es) | 2020-05-08 | 2023-01-30 | Halia Therapeutics Inc | Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). |
| CN111454261A (zh) * | 2020-05-27 | 2020-07-28 | 南京普锐达医药科技有限公司 | 一种4-氯吡咯并嘧啶化合物的合成方法 |
| IL302807A (en) * | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | GCN2 and PERK kinase inhibitors and methods of using them |
| WO2022212326A1 (en) | 2021-03-29 | 2022-10-06 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022216680A1 (en) | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2023025912A1 (en) | 2021-08-25 | 2023-03-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| TW202339730A (zh) * | 2021-12-03 | 2023-10-16 | 美商迪賽孚爾製藥有限公司 | Ｇｃｎ２及ｐｅｒｋ激酶抑制劑及其使用方法 |
| WO2023196659A1 (en) * | 2022-04-08 | 2023-10-12 | Alesta Therapeutics BV | Gcn2 modulator compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69815317T2 (de) * | 1997-03-19 | 2005-04-07 | Abbott Gmbh & Co. Kg | Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren |
| BR9913888A (pt) | 1998-09-18 | 2002-01-08 | Basf Ag | Composto, e, métodos de inibir a atividade da proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente |
| GB0625827D0 (en) * | 2006-12-22 | 2007-02-07 | Astex Therapeutics Ltd | New compounds |
| DK2358720T3 (en) | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer fused-ring |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| WO2014060432A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| JP6268276B2 (ja) | 2013-04-04 | 2018-01-24 | ヤンセン ファーマシューティカ エヌ．ベー． | ＰＥＲＫ阻害剤としての新規なＮ（２，３−ジヒドロ−１Ｈ−ピロロ［２，３−ｂ］ピリジン−５−イル）−４−キナゾリンアミン誘導体およびＮ−（２，３−ジヒドロ−１Ｈ−インドール−５−イル）−４−キナゾリンアミン誘導体 |
| KR20160013028A (ko) * | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 그에 대한 적응증 |
| WO2015136463A1 (en) | 2014-03-11 | 2015-09-17 | Glaxosmithkline Intellectual Property (No.2) Limited | Chemical compounds acting as perk inhibitors |
| KR102500416B1 (ko) * | 2016-06-21 | 2023-02-17 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체 |
-
2017
- 2017-06-19 KR KR1020197001839A patent/KR102500416B1/ko active IP Right Grant
- 2017-06-19 DK DK17732075.1T patent/DK3472165T3/da active
- 2017-06-19 AU AU2017279878A patent/AU2017279878B9/en active Active
- 2017-06-19 FI FIEP17732075.1T patent/FI3472165T3/fi active
- 2017-06-19 JP JP2018566910A patent/JP6867417B2/ja active Active
- 2017-06-19 US US16/312,061 patent/US10561660B2/en active Active
- 2017-06-19 RU RU2019101002A patent/RU2753520C2/ru active
- 2017-06-19 PT PT177320751T patent/PT3472165T/pt unknown
- 2017-06-19 ES ES17732075T patent/ES2964781T3/es active Active
- 2017-06-19 SI SI201731456T patent/SI3472165T1/sl unknown
- 2017-06-19 HU HUE17732075A patent/HUE064919T2/hu unknown
- 2017-06-19 CA CA3029097A patent/CA3029097A1/en active Pending
- 2017-06-19 EP EP17732075.1A patent/EP3472165B1/en active Active
- 2017-06-19 WO PCT/EP2017/064904 patent/WO2017220477A1/en unknown
- 2017-06-19 MX MX2018016419A patent/MX2018016419A/es unknown
- 2017-06-19 CN CN201780038709.2A patent/CN109311894B/zh active Active
-
2018
- 2018-12-16 IL IL263739A patent/IL263739B/en unknown
-
2019
- 2019-12-19 US US16/721,267 patent/US10918642B2/en active Active
-
2021
- 2021-01-04 US US17/140,471 patent/US11491158B2/en active Active
-
2022
- 2022-09-29 US US17/936,576 patent/US11833153B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| FI3472165T3 (fi) | 2023-12-11 |
| JP2019521996A (ja) | 2019-08-08 |
| RU2019101002A3 (sl) | 2020-09-30 |
| US10561660B2 (en) | 2020-02-18 |
| CA3029097A1 (en) | 2017-12-28 |
| US11491158B2 (en) | 2022-11-08 |
| US20190201406A1 (en) | 2019-07-04 |
| WO2017220477A1 (en) | 2017-12-28 |
| CN109311894B (zh) | 2022-03-22 |
| EP3472165A1 (en) | 2019-04-24 |
| DK3472165T3 (da) | 2023-12-11 |
| MX2018016419A (es) | 2019-09-09 |
| US11833153B2 (en) | 2023-12-05 |
| US20230107393A1 (en) | 2023-04-06 |
| KR102500416B1 (ko) | 2023-02-17 |
| AU2017279878B2 (en) | 2021-04-01 |
| ES2964781T3 (es) | 2024-04-09 |
| AU2017279878A1 (en) | 2019-01-31 |
| CN109311894A (zh) | 2019-02-05 |
| PT3472165T (pt) | 2023-12-12 |
| US10918642B2 (en) | 2021-02-16 |
| HUE064919T2 (hu) | 2024-04-28 |
| RU2019101002A (ru) | 2020-07-21 |
| RU2753520C2 (ru) | 2021-08-17 |
| KR20190020104A (ko) | 2019-02-27 |
| AU2017279878B9 (en) | 2021-04-29 |
| IL263739B (en) | 2022-02-01 |
| JP6867417B2 (ja) | 2021-04-28 |
| IL263739A (en) | 2019-01-31 |
| US20200121686A1 (en) | 2020-04-23 |
| US20210128563A1 (en) | 2021-05-06 |
| EP3472165B1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263739B (en) | History of n-(converted-phenyl)-sulfonamide as kinase inhibitors | |
| HK1245244A1 (zh) | 作爲激酶抑制劑的雜環酰胺 | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL304547A (en) | 3-substituted benzamide derivatives as kinase inhibitors | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| MA44607A (fr) | Inhibiteurs de kinase | |
| EP3347357A4 (en) | HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY | |
| ZA201908372B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| GB201613945D0 (en) | Compounds useful as kinase inhibitors | |
| TH1501004620A (th) | เฮทเทอโรไซคลิก เอไมด์ ในรูปสารยับยั้งไคเนส |